| [1] | Frommer L, Kahaly GJ. Autoimmune polyendocrinopathy[J]. J Clin Endocrinol Metab, 2019, 104(10): 4769-4782. doi: 10.1210/jc.2019-00602
																																					pmid: 31127843
 | 
																													
																						| [2] | Sharifinejad N, Zaki-Dizaji M, Tebyanian S, et al.  Clinical, immunological, and genetic features in 938 patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a systematic review[J]. Expert Rev Clin Immunol, 2021, 17(8): 807-817. doi: 10.1080/1744666X.2021.1925543
 | 
																													
																						| [3] | Landegren N, Pourmousa Lindberg M, Skov J, et al.  Autoantibodies targeting a collecting duct-specific water channel in tubulointerstitial nephritis[J]. J Am Soc Nephrol, 2016, 27(10): 3220-3228. pmid: 26984885
 | 
																													
																						| [4] | Tian S, Xu B, Liu Z, et al.  Autoimmune polyglandular syndrome type III associated with antineutrophil cytoplasmic autoantibody-mediated crescentic glomerulonephritis: a case report and literature review[J]. Medicine (Baltimore), 2020, 99(7): e19179. doi: 10.1097/MD.0000000000019179
 | 
																													
																						| [5] | Dikovec C, Wolters K, Vossen LM, et al.  MPO-ANCA-associated vasculitis in the context of autoimmune polyglandular syndrome type 3: case report and literature review[J]. Rheumatol Adv Pract, 2022, 6(3): rkac085. | 
																													
																						| [6] | Büyükçelik M, Keskin M, Keskin Ö, et al.  Autoimmune polyglandular syndrome type 3c with ectodermal dysplasia, immune deficiency and hemolytic-uremic syndrome[J]. J Clin Res Pediatr Endocrinol, 2014, 6(1): 47-50. doi: 10.4274/Jcrpe.1128
																																					pmid: 24637310
 | 
																													
																						| [7] | Park JH, Lee KH, Jeon B, et al.  Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: a systematic review[J]. Autoimmun Rev, 2020, 19(6): 102526. doi: 10.1016/j.autrev.2020.102526
 | 
																													
																						| [8] | Barzaghi F, Amaya Hernandez LC, Neven B, et al.  Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: an international multicenter retrospective study[J]. J Allergy Clin Immunol, 2018, 141(3): 1036-1049.e5. doi: S0091-6749(17)31893-6
																																					pmid: 29241729
 | 
																													
																						| [9] | Pham-Dobor G, Hanák L, Hegyi P, et al.  Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III[J]. J Endocrinol Invest, 2020, 43(9): 1-9. doi: 10.1007/s40618-020-01229-1
																																					pmid: 32227311
 | 
																													
																						| [10] | Colao A, Jaffrain-Rea ML, Beckers A. Polyendocrine disorders and endocrine neoplastic syndromes[M]. Switzerland: Springer Nature Switzerland AG, 2021: 5-46. | 
																													
																						| [11] | Improda N, Capalbo D, Cirillo E, et al.  Cutaneous vasculitis in patients with autoimmune polyendocrine syndrome type 1: report of a case and brief review of the literature[J]. BMC Pediatr, 2014, 14: 272. doi: 10.1186/1471-2431-14-272
																																					pmid: 25361846
 | 
																													
																						| [12] | Kurozumi A, Okada Y, Arao T, et al.  Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves' disease and type 1 diabetes mellitus: a case report[J]. Endocr J, 2015, 62(1): 69-75. doi: 10.1507/endocrj.EJ14-0152
																																					pmid: 25273396
 |